Zydus Lifesciences’ Verapamil Approval Analyzed
Zydus Lifesciences has successfully gained final approval from the U.S. Food and Drug Administration (USFDA) for its generic version of Verapamil Hydrochloride Extended-Release Tablets. This medication, available in 120mg, 180mg, and 240mg strengths, is used to control high blood pressure and lower the risk of serious heart problems. This approval represents a significant step for the company and its impact on patient healthcare.
- USFDA approved Zydus’ Verapamil Hydrochloride ER Tablets.
- This generic medication manages high blood pressure effectively.
- Annual sales reach $24.5 million in the U.S. market.
- Zydus’ approval total rises to 428 products.
- Revenue increased by 18% year-over-year to $6.038 billion.
- Net profit jumped 38% to Rs 1,258.60 crore.
The Verapamil Hydrochloride ER Tablets are a direct competitor to Calan SR Extended-Release Tablets. They work to reduce the danger of strokes and heart attacks by carefully managing blood pressure. Zydus manufactures this product at its facility in Baddi, Himachal Pradesh, ensuring quality control and efficient production.
Market data from IQVIA MAT September 2025 shows that Verapamil Hydrochloride ER Tablets are selling well, with annual sales of $24.5 million in the United States. This solid sales record highlights the product’s value and demand.
Zydus Lifesciences’ growing approval record—currently at 428—demonstrates the company’s commitment to developing and offering effective medications. Since starting ANDA filings in FY 200304, they’ve submitted 487 applications, showcasing their extensive research and development efforts.
The Zydus Group’s overall mission is to improve people’s health and well-being. They operate globally, employing over 27,000 people. Their focus on innovative healthcare solutions contributes to a healthier world.
Recent financial results show positive growth for Zydus. Revenue increased by 18.07% to Rs 6,037.9 crore, and net profit jumped 38.12% to Rs 1,258.60 crore, indicating strong performance and investment returns.
“This approval underscores Zydus Lifesciences’ dedication to providing accessible and effective cardiovascular health solutions.”
